Zinc for Cold Prevention

Zinc has decent evidence for shortening a cold once it has started. Preventing one is a much harder claim.

Cochrane reviews and subsequent meta-analyses of zinc lozenges consistently show a reduction in the duration of common cold symptoms - typically around a day or so - when high-dose lozenges are started within 24 hours of onset. This is a treatment effect, dependent on local contact with the nasopharyngeal mucosa. Prevention evidence is thinner and largely confined to specific groups. Trials in children in low-income settings and in zinc-deficient populations show reduced incidence of respiratory infections, and long-term supplementation in older adults with low zinc status has reduced infection rates. In well-nourished adults, routine zinc has not been shown to reliably prevent colds, and the case for taking it year-round on that basis is weak.

Common colds are caused mostly by rhinoviruses, which bind ICAM-1 on nasal epithelium and replicate locally. Defence depends on epithelial barrier integrity, mucosal antimicrobial peptides, interferon responses and the function of neutrophils, NK cells and T lymphocytes.

Zinc is a cofactor for hundreds of enzymes and structural zinc-finger transcription factors, and deficiency causes thymic atrophy, reduced T cell number and impaired NK activity - a well-characterised immunodeficiency that corrects with repletion. That is the plausible route to fewer infections in deficient people. The lozenge effect works differently. Free ionic zinc released in the throat may interfere with rhinovirus capsid binding and replication locally, which is why formulation matters and why zinc bound to citrate or flavourings that chelate it performs poorly. Swallowed capsules do not deliver this local exposure.

Separate the daily adequacy dose from the short high-dose lozenge protocol.

There are currently no studies linked to this pairing in our library, so no study list is shown.

Meta-analyses of zinc lozenge trials show shortened cold duration when treatment starts early, and the immunological consequences of zinc deficiency are thoroughly documented. Prevention trials in children in low-income settings and in older adults with low zinc status show reduced respiratory infection incidence, supporting a deficiency-correction effect. Against that, prevention trials in well-nourished adults are few and largely unconvincing, lozenge trials are heterogeneous in formulation and dose with common blinding failures due to taste, and effect estimates vary widely between reviews. Some formulations show no effect at all. There is no evidence that routine zinc prevents colds in people with adequate intake.

Zinc at up to 40 mg daily is safe for most adults. Nausea and metallic taste are common with lozenges, and taking zinc on an empty stomach frequently causes vomiting.

Prolonged intake above 40 mg daily induces metallothionein and blocks copper absorption, causing copper deficiency with anaemia and irreversible myeloneuropathy. Symptoms suggesting more than a cold - high fever, breathlessness, chest pain, confusion or symptoms persisting beyond ten days - warrant medical assessment rather than more lozenges.

Copper displacement and absorption timing are the recurring issues.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.